La Jolla Pharmaceutical Company is a biopharmaceutical company. The Company is focused on the discovery, development and commercialization of therapies to improve outcomes in patients suffering from life-threatening diseases. LJPC-501 is its formulation of angiotensin II for the potential treatment of catecholamine-resistant hypotension (CRH). It has initiated a Phase III trial of LJPC-501 for the treatment of CRH, called the Angiotensin II for the Treatment of High-Output Shock 3 (ATHOS) Phase III trial. LJPC-401 is its formulation of synthetic human hepcidin for the potential treatment of conditions characterized by iron overload, such as hereditary hemochromatosis, beta thalassemia, sickle cell disease and myelodysplastic syndrome. LJPC-30S is its next-generation gentamicin derivative program that is focused on therapeutics for the potential treatment of serious bacterial infections, as well as rare genetic disorders, such as cystic fibrosis and Duchenne muscular dystrophy.
Industry, Sector and Symbol:
- Sector: Healthcare
- Industry: Bio Therapeutic Drugs
- Sub-Industry: N/A
- Symbol: NASDAQ:LJPC
- CUSIP: N/A
- Web: www.ljpc.com
Capitalization:- Market Cap: $753.3 million
- Outstanding Shares: 22,123,000
Average Prices:- 50 Day Moving Avg: $30.29
- 200 Day Moving Avg: $27.87
- 52 Week Range: $14.63 - $39.28
P/E:- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -9.70
- P/E Growth: -0.53
Sales & Book Value:- Annual Revenue: $381,999.00
- Price / Sales: 1,955.75
- Book Value: $7.04 per share
- Price / Book: 4.80
Profitability:- EBIDTA: ($84,240,000.00)
- Return on Equity: -88.74%
- Return on Assets: -78.07%
Debt:- Current Ratio: 28.99%
- Quick Ratio: 28.99%
Misc:- Average Volume: 370,456 shs.
- Beta: 1.67
- Short Ratio: 12.15
Frequently Asked Questions for La Jolla Pharmaceutical Company (NASDAQ:LJPC)
What is La Jolla Pharmaceutical Company's stock symbol?
La Jolla Pharmaceutical Company trades on the NASDAQ under the ticker symbol "LJPC."
How were La Jolla Pharmaceutical Company's earnings last quarter?
La Jolla Pharmaceutical Company (NASDAQ:LJPC) released its quarterly earnings results on Thursday, April, 27th. The company reported ($1.26) earnings per share for the quarter, topping the Zacks' consensus estimate of ($1.34) by $0.08. View La Jolla Pharmaceutical Company's Earnings History.
Where is La Jolla Pharmaceutical Company's stock going? Where will La Jolla Pharmaceutical Company's stock price be in 2017?
6 equities research analysts have issued 1 year target prices for La Jolla Pharmaceutical Company's shares. Their predictions range from $34.00 to $57.00. On average, they expect La Jolla Pharmaceutical Company's share price to reach $45.20 in the next year. View Analyst Ratings for La Jolla Pharmaceutical Company.
What are analysts saying about La Jolla Pharmaceutical Company stock?
Here are some recent quotes from research analysts about La Jolla Pharmaceutical Company stock:
- 1. According to Zacks Investment Research, "LA JOLLA PHARMACEUTICAL CO. is engaged in the research and development of therapeutic products for the treatment of autoimmune and inflammatory diseases. " (7/18/2017)
- 2. Cowen and Company analysts commented, "LJPC reported Q1 financials." (4/28/2017)
- 3. Chardan Capital analysts commented, "We believe the results are compelling and, based on the SPA, will likely result in LJPC-501 US approval. Recall from our 24 January 2017 note where we discussed the SPA, stating with regards to the primary endpoint," (3/2/2017)
- 4. SunTrust Banks, Inc. analysts commented, "strong" ATHOS-3 data which implies LJPC-501 could be standard-of-care in last-line CRH.Suneja commented, "We believe today's highly favorable ATHOS-3 data (primary endpoint met; positive trend in mortality) are supportive of approval in CRH, which could be at least $500MM opportunity; an NDA filing is expected in 2H17 and full data are expected in 2017 at a major medical conference and publication in a "top-tier" journal. In our view, these results provide validation for LJPC's capital-efficient strategy of developing naturally occurring peptides with well-understood biological functions for life-threatening diseases. We reiterate our Buy rating and increase our NPV-derived PT to $57 from $38." (2/27/2017)
Who are some of La Jolla Pharmaceutical Company's key competitors?
Some companies that are related to La Jolla Pharmaceutical Company include Array BioPharma (ARRY), Acceleron Pharma (XLRN), Dermira (DERM), Clinigen Group PLC (CLIN), Xencor (XNCR), Amarin Corporation PLC (AMRN), Insmed (INSM), Forward Pharma A/S (FWP), Acorda Therapeutics (ACOR), NeuroDerm (NDRM), Omeros Corporation (OMER), Aduro Biotech (ADRO), Synergy Pharmaceuticals (SGYP), Achaogen (AKAO), Ascendis Pharma A/S (ASND), Five Prime Therapeutics (FPRX), PTC Therapeutics (PTCT) and Insys Therapeutics (INSY).
Who are La Jolla Pharmaceutical Company's key executives?
La Jolla Pharmaceutical Company's management team includes the folowing people:
- Kevin C. Tang, Chairman of the Board
- George F. Tidmarsh M.D. Ph.D., President, Chief Executive Officer, Secretary, Director
- Dennis M. Mulroy CPA, Chief Financial Officer
- Jennifer A. Carver, Senior Vice President,Operations
- Lakhmir S. Chawla M.D., Chief Medical Officer
- Laura Douglass, Independent Director
- Craig A. Johnson, Independent Director
- Robert Harvey Rosen, Independent Director
Who owns La Jolla Pharmaceutical Company stock?
La Jolla Pharmaceutical Company's stock is owned by a number of of institutional and retail investors. Top institutional investors include Hollencrest Securities LLC (0.10%). Company insiders that own La Jolla Pharmaceutical Company stock include Dennis Mulroy, George F Tidmarsh, Kevin C Tang and Lakhmir S Chawla. View Institutional Ownership Trends for La Jolla Pharmaceutical Company.
How do I buy La Jolla Pharmaceutical Company stock?
Shares of La Jolla Pharmaceutical Company can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is La Jolla Pharmaceutical Company's stock price today?
One share of La Jolla Pharmaceutical Company stock can currently be purchased for approximately $33.77.
MarketBeat Community Rating for La Jolla Pharmaceutical Company (NASDAQ LJPC)MarketBeat's community ratings are surveys of what our community members think about La Jolla Pharmaceutical Company and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Consensus Ratings for La Jolla Pharmaceutical Company (NASDAQ:LJPC) (How are Consensus Ratings Calculated?) MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
| Ratings Breakdown: | 6 Buy Ratings |
| Consensus Rating: | Buy (Score: 3.00) |
| Consensus Price Target: | $45.20 (33.85% upside) |
Analysts' Ratings History for La Jolla Pharmaceutical Company (NASDAQ:LJPC)
Show:
| Date | Firm | Action | Rating | Price Target | Impact on Share Price | Details |
|---|
| 7/25/2017 | Jefferies Group LLC | Reiterated Rating | Buy | $40.00 | Low |  |
| 5/22/2017 | Chardan Capital | Set Price Target | Buy | $34.00 | Low | |
| 5/22/2017 | SunTrust Banks, Inc. | Reiterated Rating | Buy | $57.00 | Medium | |
| 4/30/2017 | Noble Financial | Reiterated Rating | Buy | | Low | |
| 4/28/2017 | Cowen and Company | Reiterated Rating | Buy | $55.00 | Low | |
| 2/28/2017 | J P Morgan Chase & Co | Reiterated Rating | Buy | $27.00 -> $40.00 | N/A | |
| 5/24/2016 | Lake Street Capital | Initiated Coverage | Buy | $25.00 | N/A | |
(Data available from 7/26/2015 forward)
Earnings History for La Jolla Pharmaceutical Company (NASDAQ:LJPC)Earnings History by Quarter for La Jolla Pharmaceutical Company (NASDAQ LJPC)| Date | Quarter | Consensus Estimate | Actual EPS | Revenue Estimate | Actual Revenue | Release Link | Conference Call | Details |
|---|
| 4/27/2017 | Q1 2017 | ($1.34) | ($1.26) | $0.17 million | | View | N/A | |
| 2/23/2017 | Q4 2016 | ($1.20) | ($1.44) | $0.16 million | $0.09 million | View | N/A | |
| 11/3/2016 | Q3 | ($0.97) | ($1.23) | $0.26 million | $0.04 million | View | N/A | |
| 8/8/2016 | Q2 | ($0.99) | ($0.90) | $0.25 million | $0.25 million | View | N/A | |
| 5/6/2016 | Q416 | ($0.74) | ($0.96) | $0.43 million | $0.23 million | View | N/A | |
| 2/25/2016 | Q4 | ($0.72) | ($0.69) | | $0.41 million | View | N/A | |
| 11/6/2015 | Q315 | ($0.69) | ($0.70) | | $0.65 million | View | N/A | |
| 8/7/2015 | Q215 | ($0.61) | ($0.70) | | | View | N/A | |
| 3/16/2015 | Q414 | ($0.37) | ($0.45) | | | View | N/A | |
| 11/12/2014 | Q314 | ($0.42) | ($0.37) | | | View | N/A | |
| 8/14/2014 | Q214 | ($0.69) | ($0.63) | | | View | N/A | |
| 4/30/2014 | Q1 2014 | ($0.91) | ($0.93) | | | View | N/A | |
| 3/31/2014 | | ($0.24) | ($0.07) | | | View | N/A | |
(Data available from 1/1/2011 forward)
Earnings Estimates for La Jolla Pharmaceutical Company (NASDAQ:LJPC)2017 EPS Consensus Estimate: ($4.81)
| Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
|---|
| Q1 2017 | 2 | ($1.39) | ($1.25) | ($1.32) |
| Q2 2017 | 2 | ($1.26) | ($1.01) | ($1.14) |
| Q3 2017 | 2 | ($1.22) | ($1.10) | ($1.16) |
| Q4 2017 | 2 | ($1.19) | ($1.19) | ($1.19) |
(Data provided by Zacks Investment Research)
Dividend History for La Jolla Pharmaceutical Company (NASDAQ:LJPC)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for La Jolla Pharmaceutical Company (NASDAQ:LJPC)Insider Ownership Percentage: 26.43%
Insider Trades by Quarter for La Jolla Pharmaceutical Company (NASDAQ:LJPC)| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Details |
|---|
| 3/23/2017 | Kevin C Tang | Director | Buy | 149,254 | $33.50 | $5,000,009.00 | |
| 3/3/2017 | Dennis Mulroy | CFO | Buy | 500 | $33.95 | $16,975.00 | |
| 3/3/2017 | George F Tidmarsh | CEO | Buy | 3,000 | $34.17 | $102,510.00 | |
| 3/3/2017 | Lakhmir S Chawla | Insider | Buy | 1,600 | $34.80 | $55,680.00 | |
| 9/13/2016 | Kevin C Tang | Director | Buy | 139,035 | $19.82 | $2,755,673.70 | |
| 3/4/2016 | Kevin C Tang | Director | Buy | 20,000 | $19.85 | $397,000.00 | |
| 3/1/2016 | George F Tidmarsh | CEO | Buy | 2,000 | $16.57 | $33,140.00 | |
| 9/28/2015 | Lakhmir S Chawla | Insider | Buy | 485 | $27.75 | $13,458.75 | |
| 9/10/2015 | Kevin C Tang | Director | Buy | 80,000 | $38.00 | $3,040,000.00 | |
| 8/21/2015 | Kevin C Tang | Director | Buy | 170,000 | $27.11 | $4,608,700.00 | |
| 6/26/2015 | Kevin C Tang | Director | Buy | 110,000 | $23.58 | $2,593,800.00 | |
| 6/24/2015 | Kevin C Tang | Director | Buy | 220,000 | $22.23 | $4,890,600.00 | |
| 6/23/2015 | Kevin C Tang | Director | Buy | 53,836 | $22.27 | $1,198,927.72 | |
| 6/22/2015 | Kevin C Tang | Director | Buy | 77,850 | $21.41 | $1,666,768.50 | |
| 5/13/2015 | Kevin C Tang | Director | Buy | 190,583 | $18.24 | $3,476,233.92 | |
| 5/12/2015 | George F Tidmarsh | CEO | Buy | 4,000 | $18.37 | $73,480.00 | |
| 12/15/2014 | Kevin C Tang | Director | Buy | 232,343 | $12.84 | $2,983,284.12 | |
| 12/11/2014 | George F Tidmarsh | CEO | Buy | 4,000 | $11.38 | $45,520.00 | |
| 9/26/2014 | George F Tidmarsh | CEO | Buy | 2,000 | $9.35 | $18,700.00 | |
| 9/26/2014 | Kevin C Tang | Director | Buy | 169,555 | $9.14 | $1,549,732.70 | |
| 9/25/2014 | Kevin C Tang | Director | Buy | 30,500 | $9.17 | $279,685.00 | |
| 9/24/2014 | Kevin C Tang | Director | Buy | 95,000 | $9.10 | $864,500.00 | |
| 9/18/2014 | George F Tidmarsh | CEO | Buy | 5,000 | $9.18 | $45,900.00 | |
| 7/23/2014 | George F Tidmarsh | CEO | Buy | 19,000 | $10.50 | $199,500.00 | |
| 5/21/2014 | George Tidmarsh | CEO | Buy | 12,000 | $7.37 | $88,440.00 | |
| 4/14/2014 | George Tidmarsh | CEO | Buy | 8,000 | $9.53 | $76,240.00 | |
| 2/7/2014 | George F Tidmarsh | CEO | Buy | 3,000 | $7.25 | $21,750.00 | |
(Data available from 1/1/2013 forward)
Headline Trends for La Jolla Pharmaceutical Company (NASDAQ:LJPC)
Latest Headlines for La Jolla Pharmaceutical Company (NASDAQ:LJPC)
| Source: |
|
| Date | Headline |
|---|
 | ETFs with exposure to La Jolla Pharmaceutical Co. : July 24, 2017
finance.yahoo.com - July 25 at 2:49 AM |
 | La Jolla Pharmaceutical Company (LJPC) Expected to Post Quarterly Sales of $170,000.00
www.americanbankingnews.com - July 16 at 10:48 AM |
| ETFs with exposure to La Jolla Pharmaceutical Co. : July 14, 2017
finance.yahoo.com - July 15 at 5:52 AM |
| La Jolla Pharmaceutical Company (NASDAQ:LJPC) Given Consensus Rating of "Buy" by Brokerages
www.americanbankingnews.com - July 14 at 5:05 PM |
| -$1.13 EPS Expected for La Jolla Pharmaceutical Company (NASDAQ:LJPC) This Quarter
www.americanbankingnews.com - July 14 at 11:18 AM |
| La Jolla Pharmaceutical Company (NASDAQ:LJPC) Rating Increased to Buy at Zacks Investment Research
www.americanbankingnews.com - July 2 at 9:36 AM |
| La Jolla Pharmaceutical Co. breached its 50 day moving average in a Bullish Manner : LJPC-US : June 22, 2017
finance.yahoo.com - June 22 at 12:32 PM |
| $170,000.00 in Sales Expected for La Jolla Pharmaceutical Company (LJPC) This Quarter
www.americanbankingnews.com - June 21 at 8:28 AM |
| Analysts Expect La Jolla Pharmaceutical Company (LJPC) Will Post Earnings of -$1.10 Per Share
www.americanbankingnews.com - June 20 at 12:12 AM |
| La Jolla Pharmaceutical Company (LJPC) Receives Average Rating of "Buy" from Analysts
www.americanbankingnews.com - June 19 at 4:38 PM |
 | Today's Research Report Coverage on Biotech Stocks -- Cyclacel Pharma, Cytori Therapeutics, La Jolla Pharma, and Moleculin Biotech
www.prnewswire.com - June 19 at 11:52 AM |
| ETFs with exposure to La Jolla Pharmaceutical Co. : June 15, 2017
finance.yahoo.com - June 16 at 7:22 AM |
| Sorrento Therapeutics (SRNE) vs. La Jolla Pharmaceutical Company (LJPC) Financial Contrast
www.americanbankingnews.com - June 11 at 4:20 PM |
| La Jolla Pharmaceutical Co. breached its 50 day moving average in a Bearish Manner : LJPC-US : June 8, 2017
finance.yahoo.com - June 8 at 9:37 AM |
| La Jolla Pharmaceutical Company (LJPC) Raised to "Hold" at ValuEngine
www.americanbankingnews.com - June 4 at 9:20 AM |
| La Jolla Pharmaceutical Co. breached its 50 day moving average in a Bearish Manner : LJPC-US : May 29, 2017
finance.yahoo.com - May 29 at 9:15 AM |
| Short Interest in La Jolla Pharmaceutical Company (LJPC) Expands By 0.7%
www.americanbankingnews.com - May 25 at 11:05 AM |
| La Jolla Pharmaceutical Company (LJPC) Given a $34.00 Price Target by Chardan Capital Analysts
www.americanbankingnews.com - May 23 at 6:58 PM |
| La Jolla Pharmaceutical Company (LJPC) Receives Average Rating of "Buy" from Brokerages
www.americanbankingnews.com - May 23 at 4:16 PM |
| SunTrust Banks, Inc. Reaffirms Buy Rating for La Jolla Pharmaceutical Company (LJPC)
www.americanbankingnews.com - May 22 at 8:22 PM |
 | Full Phase 3 La Jolla Pharmaceutical Data Creates A Great Short Opportunity
seekingalpha.com - May 22 at 5:41 PM |
 | La Jolla Meets ATHOS-3 Trial Endpoints, Dispels Market Controversy In The Process - Benzinga
www.benzinga.com - May 22 at 10:20 AM |
 | Results of ATHOS-3 Phase 3 Study of LJPC-501 Published in The New England Journal of Medicine - Business Wire (press release)
www.businesswire.com - May 22 at 10:20 AM |
| Mixed Outcomes for La Jolla Pharma Shock Drug Fuels Debate Over Sales Potential
finance.yahoo.com - May 21 at 5:39 PM |
| Results of ATHOS-3 Phase 3 Study of LJPC-501 Published in The New England Journal of Medicine
finance.yahoo.com - May 21 at 5:39 PM |
 | Here's Why La Jolla Pharmaceuticals Company Is Soaring - Motley Fool
www.fool.com - May 19 at 6:00 PM |
| Here's Why La Jolla Pharmaceuticals Company Is Soaring
finance.yahoo.com - May 19 at 10:51 AM |
| La Jolla Pharmaceutical Co. breached its 50 day moving average in a Bullish Manner : LJPC-US : May 19, 2017
finance.yahoo.com - May 19 at 10:51 AM |
| Implied Volatility Surging for La Jolla Pharmaceutical (LJPC) Stock Options
finance.yahoo.com - May 19 at 10:51 AM |
| La Jolla Pharmaceutical Company (LJPC) Expected to Post Earnings of -$1.13 Per Share
www.americanbankingnews.com - May 1 at 9:00 PM |
| La Jolla Pharmaceutical Company (LJPC) Issues Quarterly Earnings Results, Beats Expectations By $0.08 EPS
www.americanbankingnews.com - May 1 at 6:48 PM |
| La Jolla Pharmaceutical Company's (LJPC) Buy Rating Reaffirmed at Noble Financial
www.americanbankingnews.com - April 30 at 7:35 AM |
| Positive Press Coverage Somewhat Likely to Affect La Jolla Pharmaceutical Company (LJPC) Share Price
www.americanbankingnews.com - April 29 at 10:47 PM |
| Cowen and Company Reaffirms Buy Rating for La Jolla Pharmaceutical Company (LJPC)
www.americanbankingnews.com - April 29 at 1:01 AM |
 | BRIEF-La Jolla Pharmaceutical quarterly loss per share $1.26
www.reuters.com - April 28 at 7:14 PM |
| La Jolla Pharmaceutical Company (LJPC) Given Average Recommendation of "Buy" by Analysts
www.americanbankingnews.com - April 28 at 6:43 PM |
| La Jolla Pharmaceutical Company Announces Financial Results for the Three Months Ended March 31, 2017 and ... - Business Wire (press release)
www.businesswire.com - April 28 at 9:33 AM |
| La Jolla Pharmaceutical Company Announces Financial Results for the Three Months Ended March 31, 2017 and Recent Corporate Progress
finance.yahoo.com - April 27 at 6:52 PM |
 | La Jolla Pharmaceutical posts 1Q loss
marketbeat.com - April 27 at 6:48 PM |
| Somewhat Favorable Media Coverage Likely to Impact La Jolla Pharmaceutical Company (LJPC) Stock Price
www.americanbankingnews.com - April 26 at 10:42 PM |
| La Jolla Pharmaceutical Co. – Value Analysis (NASDAQ:LJPC) : April 24, 2017
finance.yahoo.com - April 24 at 7:03 PM |
| La Jolla Pharmaceutical Company (LJPC) to Post Q2 2017 Earnings of ($1.26) Per Share, SunTrust Banks Forecasts
www.americanbankingnews.com - April 24 at 7:59 AM |
| La Jolla Pharmaceutical Company (LJPC) Given Daily Coverage Optimism Score of 0.31
www.americanbankingnews.com - April 23 at 6:15 PM |
| La Jolla Pharmaceutical Co. breached its 50 day moving average in a Bullish Manner : LJPC-US : April 21, 2017
finance.yahoo.com - April 21 at 10:05 AM |
| Somewhat Positive Media Coverage Very Likely to Impact La Jolla Pharmaceutical Company (LJPC) Stock Price
www.americanbankingnews.com - April 16 at 2:15 PM |
| Brokerages Expect La Jolla Pharmaceutical Company (LJPC) to Post -$1.34 EPS
www.americanbankingnews.com - April 10 at 2:28 PM |
| La Jolla Pharmaceutical Company (LJPC) Given Average Rating of "Buy" by Analysts
www.americanbankingnews.com - April 6 at 1:34 PM |
 | La Jolla Pharmaceutical (LJPC) puts active after short report hits
www.streetinsider.com - April 4 at 8:20 AM |
| La Jolla Pharmaceutical Company (LJPC) Rating Reiterated by Jefferies Group LLC
www.americanbankingnews.com - March 29 at 10:16 PM |
| Kevin C. Tang Acquires 149,254 Shares of La Jolla Pharmaceutical Company (LJPC) Stock
www.americanbankingnews.com - March 27 at 10:25 PM |
La Jolla Pharmaceutical Company (LJPC) Chart for Wednesday, July, 26, 2017
